Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras JO McNamara, ER Andrechek, Y Wang, KD Viles, RE Rempel, E Gilboa, ... Nature biotechnology 24 (8), 1005-1015, 2006 | 1324 | 2006 |
Aptamers: an emerging class of therapeutics SM Nimjee, CP Rusconi, BA Sullenger Annu. Rev. Med. 56 (1), 555-583, 2005 | 1204 | 2005 |
Notch promotes radioresistance of glioma stem cells J Wang, TP Wakeman, JD Lathia, AB Hjelmeland, XF Wang, RR White, ... Stem cells 28 (1), 17-28, 2010 | 783 | 2010 |
In vivo activity of nuclease-resistant siRNAs JM Layzer, AP McCaffrey, AK Tanner, ZAN Huang, MA Kay, BA Sullenger Rna 10 (5), 766-771, 2004 | 775 | 2004 |
RNA aptamers as reversible antagonists of coagulation factor IXa CP Rusconi, E Scardino, J Layzer, GA Pitoc, TL Ortel, D Monroe, ... Nature 419 (6902), 90-94, 2002 | 678 | 2002 |
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication BA Sullenger, HF Gallardo, GE Ungers, E Gilboa Cell 63 (3), 601-608, 1990 | 618 | 1990 |
Emerging clinical applications of RNA BA Sullenger, E Gilboa Nature 418 (6894), 252-258, 2002 | 574 | 2002 |
Aptamers as therapeutics SM Nimjee, RR White, RC Becker, BA Sullenger Annual review of pharmacology and toxicology 57 (1), 61-79, 2017 | 529 | 2017 |
Antidote-mediated control of an anticoagulant aptamer in vivo CP Rusconi, JD Roberts, GA Pitoc, SM Nimjee, RR White, G Quick Jr, ... Nature biotechnology 22 (11), 1423-1428, 2004 | 452 | 2004 |
Developing aptamers into therapeutics RR White, BA Sullenger, CP Rusconi The Journal of clinical investigation 106 (8), 929-934, 2000 | 392 | 2000 |
Generation of species cross-reactive aptamers using “toggle” SELEX R White, C Rusconi, E Scardino, A Wolberg, J Lawson, M Hoffman, ... Molecular Therapy 4 (6), 567-573, 2001 | 383 | 2001 |
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice JO McNamara, D Kolonias, F Pastor, RS Mittler, L Chen, PH Giangrande, ... The Journal of clinical investigation 118 (1), 376-386, 2008 | 363 | 2008 |
Ribozyme-mediated repair of defective mRNA by targeted trans-splicing BA Sullenger, TR Cech Nature 371 (6498), 619-622, 1994 | 355 | 1994 |
In vivo selection of tumor-targeting RNA motifs J Mi, Y Liu, ZN Rabbani, Z Yang, JH Urban, BA Sullenger, BM Clary Nature chemical biology 6 (1), 22-24, 2010 | 339 | 2010 |
Gene therapy progress and prospects: RNA aptamers NS Que-Gewirth, BA Sullenger Gene therapy 14 (4), 283-291, 2007 | 286 | 2007 |
Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer NJ Ganson, TJ Povsic, BA Sullenger, JH Alexander, SL Zelenkofske, ... Journal of Allergy and Clinical Immunology 137 (5), 1610-1613. e7, 2016 | 276 | 2016 |
Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA BA Sullenger, TR Cech Science 262 (5139), 1566-1569, 1993 | 276 | 1993 |
Ribozyme-mediated repair of sickle β-globin mRNAs in erythrocyte precursors N Lan, RP Howrey, SW Lee, CA Smith, BA Sullenger Science 280 (5369), 1593-1596, 1998 | 274 | 1998 |
From the RNA world to the clinic BA Sullenger, S Nair Science 352 (6292), 1417-1420, 2016 | 264 | 2016 |
Group II introns designed to insert into therapeutically relevant DNA target sites in human cells H Guo, M Karberg, M Long, JP Jones III, B Sullenger, AM Lambowitz science 289 (5478), 452-457, 2000 | 264 | 2000 |